title: Rotavirus vaccines in Israel: Uptake and impact.
abstract: We present an overview of the impact of universal rotavirus immunization with the pentavalent vaccine, RotaTeq, which was introduced in Israel in 2010. The vaccine is given free of charge at age 2, 4 and 6 months, with an 80% coverage that was shortly achieved during the universal immunization period. Compared to pre-universal immunization years (2008-2010), a reduction of 66-68% in the incidence of rotavirus gastroenteritis (RVGE) hospitalizations was observed in 2011-2015 among children aged 0-23 months in central and northern Israel. In southern Israel a reduction of 80-88% in RVGE hospital visit rate was found among Jewish children aged 0-23 months in 2011-2013. Among Bedouins, the respective decline was 62-75%. A significant reduction of 59% was also observed in RVGE clinic visits, presumably representing less severe illness. Indirect benefit was evident in children aged 24-59 months who were ineligible for universal immunization. Vaccine effectiveness against RVGE hospitalization was estimated at 86% in children aged 6-23 months. Changes in the circulating rotavirus genotypes occurred but the contribution of vaccine induced immune pressure is unclear. Universal rotavirus immunization was followed by an impressive decrease in the burden of RVGE in young children in Israel, likely attributed to good vaccine coverage and effectiveness.
authors.affiliation: a Department of Epidemiology and Preventive Medicine , School of Public Health, Sackler Faculty of Medicine, Tel Aviv University , Ramat Aviv , Tel Aviv , Israel.
authors.forename: Khitam
authors.initials: K
authors.lastname: Muhsen
authors.affiliation: a Department of Epidemiology and Preventive Medicine , School of Public Health, Sackler Faculty of Medicine, Tel Aviv University , Ramat Aviv , Tel Aviv , Israel.
authors.forename: Daniel
authors.initials: D
authors.lastname: Cohen
mesh_terms: D005759:Gastroenteritis / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D017589:Immunization Programs; D007115:Immunization Schedule; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007557:Israel / Q000453:epidemiology; D012400:Rotavirus Infections / Q000453:epidemiology* / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage*; D016896:Treatment Outcome; D000073887:Vaccination Coverage; D014613:Vaccines, Attenuated / Q000008:administration & dosage
chemical_list: C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated
keywords: Israel; RotaTeq; effectiveness; impact; rotavirus; universal immunization